Mesenchymal Stem Cells for Prevention of Bronchopulmonary Dysplasia in Infants

• ClinicalTrials.gov Identifier: NCT03631420
• Recruitment Status: Recruiting
• First Posted: August 15, 2018
• Last Update Posted: December 7, 2022
• Sponsor: Meridigen Biotech Co., Ltd.
• Information provided by (Responsible Party): Meridigen Biotech Co., Ltd.

Study Description

Brief Summary:

The clinical study with UMC119-01 is designed to investigate the safety in patients with bronchopulmonary dysplasia ("BPD"). This will be a dose escalation, open-label, single-center study in infants at high risk for BPD.

Condition or disease	Intervention/treatment	Phase
Bronchopulmonary Dysplasia	Biological: Human Umbilical Cord Derived-Mesenchymal Stem Cells	Phase 1

Detailed Description:

UMC119-01 is ex vivo cultured human umbilical cord tissue-derived mensenchymal stem cells product which is intended for prevention of Bronchopulmonary dysplasia.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 9 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Prevention
• Official Title: The Safety and Feasibility of UMC119-01 Cell Therapy in Infants at High Risk for Bronchopulmonary Dysplasia
• Actual Study Start Date: October 26, 2018
• Estimated Primary Completion Date: December 31, 2025
• Estimated Study Completion Date: July 31, 2027

Arms and Interventions

Arm	Intervention/treatment
Experimental: UMC119-01; UMC119-01 is ex vivo cultured human umbilical cord tissue-derived mensenchymal stem cells product	Biological: Human Umbilical Cord Derived-Mesenchymal Stem Cells; Cohort 1 : 3 million cells/kg ; Cohort 2 : 10 million cells/kg ; Cohort 3 : 30 million cells/kg

Outcome Measures

Primary Outcome Measures :

1. The incidence and frequency of adverse events related to administration of UMC119-01. [ Time Frame: 3 months from the day of administration ]
   • The incidence and frequency of adverse events (AEs) and serious adverse events (SAEs), including their relationship to the administration of UMC119 01.

Secondary Outcome Measures :

1. The percentage of subjects who died from any cause during the study. [ Time Frame: 3 months from the day of administration ]
   The percentage of subjects who died from any cause during the study.
2. Changes of the oxygen saturation. [ Time Frame: 3 months from the day of administration ]
   Changes from baseline of the oxygen saturation.
3. Changes of chest x-ray findings in participants before and after administration. [ Time Frame: 3 months from the day of administration ]
   Changes from baseline to 3 months of chest x-ray findings in participants before and after administration.
4. Changes of inflammatory markers (pg/ml) before and after administration. [ Time Frame: 3 days and 7 days after administration ]
   Changes from baseline of inflammatory markers (pg/ml) .
5. Comparison of the incidence and severity of preterm children's complications in participants before and after administration. [ Time Frame: 3 months from the day of administration ]
   Comparison of the incidence and severity of preterm children's complications in participants before and after administration.
6. The number of days of intubation, or where ventilator or oxygen therapy. [ Time Frame: 3 months from the day of administration ]
   The number of days of intubation, or where ventilator or oxygen therapy.
7. Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA). [ Time Frame: 36 weeks postmenstrual age (PMA) ]
   Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA).

Eligibility Criteria

• Ages Eligible for Study: 3 Days to 51 Days (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Neonatal infants who fulfil all of the following criteria will be enrolled:

1. Subjects of postnatal age between 3 to 30 days.
2. Are male and female infants born at GA between 23 weeks to 29 weeks. The postmenstrual age of subject received UMC119-01 should be no more than PMA36 weeks.
3. Subjects with birth weight between 501g to 1249 g.
4. Have endotracheal tube in place as part of SoC for preterm infants with BPD at screening and on treatment visit (Day 0), and that they will have not been intubated for the purposes of this study.
5. A subject who is intubated and receiving mechanical ventilation with a fraction of inspired oxygen (FiO2) of 0.25 or greater at Screening.
6. A subject who has had either a deterioration or no change in the setting of mechanical ventilation within the 24 hours before trial enrollment.
7. Written informed consent has been provided by the subject's parents, legal guardians, or a legal representative, who agree to comply with all of the study procedures, including those in the long-term safety surveillance period.

Exclusion Criteria:

Neonatal infants who meet any of the following criteria will be excluded:

1. Have a major congenital abnormality, including neurological (including anencephaly and similar malformations), hepatic, renal, cardiovascular abnormality (except for patent ductus arteriosus, PDA).
2. Have a known genetic syndrome.
3. Have a condition that makes them ineligible for participation in this study, as determined by the investigator.
4. Have C-reactive protein (CRP) >30 mg/L; or any infections including pneumonia, sepsis, or shock.
5. Have pre-existing severe intraventricular hemorrhage (IVH) (grade ≥3).
6. Have active pulmonary hemorrhage or air leak syndrome.
7. Have abnormal hepatic (AST, ALT >150 U/L or direct bilirubin >2 mg/dL or total bilirubin >15 mg/dL) or renal function (serum creatinine >1 mg/dL or oliguria).
8. Are known to be infected with HIV or CMV.
9. Are expected to have surgery within 24 hours prior to and/or after UMC119 01 instillation.
10. Are expected to receive any other intratracheal treatments, including surfactant within 72 hours prior to and/or after UMC119 01 instillation.
11. Are currently participating in any other interventional clinical trial.

Contacts and Locations

Contacts

Contact: Katherine Huang, MS; +886-2-26275175 ext 19926; Katherine.Huang@meridigen.com

Locations

Taiwan

National Chen-Kung University Hospital; Recruiting

Tainan City, Taiwan

Contact: Katherine Huang, MS +886-2-2627-5175 ext 19926 Katherine.Huang@meridigen.com

Principal Investigator: Yuh-Jyh Lin, MD

Sub-Investigator: Yung-Chieh Lin, MD

Sub-Investigator: Yu-Shan Chang, MD

Sub-Investigator: Yen-Ju Chen, MD

Sponsors and Collaborators

Meridigen Biotech Co., Ltd.

More Information

• Responsible Party: Meridigen Biotech Co., Ltd.
• ClinicalTrials.gov Identifier: NCT03631420
• Other Study ID Numbers: UMC119-01-001
• First Posted: August 15, 2018
• Last Update Posted: December 7, 2022
• Last Verified: December 2022

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Bronchopulmonary Dysplasia; Ventilator-Induced Lung Injury; Lung Injury; Lung Diseases; Respiratory Tract Diseases; Infant, Premature, Diseases; Infant, Newborn, Diseases